BPT Crunch

Companies on the Cutting Edge of Healthcare Innovations

back to Marketplace

Silicon Therapeutics

Silicon Therapeutics logo

Founded
2016
Geography
United States of America based
Funding
$21.200 M

Silicon Therapeutics is an integrated physics driven drug discovery company focused on developing novel medicines for diseases with targets that are currently considered to be challenging for traditional approaches. Our platform closely represents the real dynamical nature of targets using accurate all-atom simulations, enabling us to design and optimize compounds for targets that were previously considered "undruggable."​ Our science, our team, and our mission are focused on applying advanced computational technologies to build and progress a pipeline of innovative medicines for patients. Silicon Therapeutics is headquartered in Boston, MA, USA with offices in Shanghai, China.


molecular simulation thermodynamics quantum mechanics

Technologies

AI Companies (Drug Discovery)   Pharmaceutical and Drug Discovery   Quantum Theory in Drug Discovery  


Posts Mentioning This Company

New Tools, Products and Technologies

R&D Platform

The Silicon Therapeutics physics-driven drug design platform combines quantum physics, statistical thermodynamics, molecular simulations, a dedicated HPC super-computing cluster, purpose-built software, in-house laboratory and clinical development capabilities.


Pipelines

STING Agonist
Clinical  |  Visit website

STimulator of Interferon Genes (STING) is a master regulator of type I interferons and a key mediator of innate immunity. Activation of STING provides two critical anti-tumor responses:

- The “spark” for initiating a robust innate immune response.
- Priming and activation of a potent T cell mediated anti-tumor adaptive response.

STING Agonist Combo
Preclinical  |  Visit website

STimulator of Interferon Genes (STING) is a master regulator of type I interferons and a key mediator of innate immunity. Activation of STING provides two critical anti-tumor responses:

- The “spark” for initiating a robust innate immune response.
- Priming and activation of a potent T cell mediated anti-tumor adaptive response.

STING Vaccine Adjuvant Platform
Preclinical  |  Visit website

STimulator of Interferon Genes (STING) is a master regulator of type I interferons and a key mediator of innate immunity. Activation of STING provides two critical anti-tumor responses:

- The “spark” for initiating a robust innate immune response.
- Priming and activation of a potent T cell mediated anti-tumor adaptive response.

Products

 

Services

No services posted yet